Oncology & Cancer

Prostate cancer diagnoses down from 2011 to 2013

(HealthDay)—From 2011 to 2013 there was a decrease in prostate cancer (PC) diagnoses, especially for younger men and low-risk disease, according to a research letter published online June 23 in JAMA Oncology.

Oncology & Cancer

Clinical trial hits new target in war on breast cancer

Breast cancers are defined by their drivers – estrogen and progesterone receptors (ER and PR) and HER2 are the most common, and there are drugs targeting each. When breast cancer has an unknown driver, it also has fewer ...

Oncology & Cancer

Prostate cancer treatment linked to dementia risk

New research has highlighted a possible link between a prostate cancer treatment called androgen deprivation therapy (ADT) and the risk of dementia. The findings are published today (Wednesday 3 July) in the Journal JAMA ...

Oncology & Cancer

Heterogeneity of PET/CT imaging phenotype prognostic in mCRPC

(HealthDay)—Metastatic castration-resistant prostate cancer (mCRPC) has heterogeneity in positron emission tomography (PET)/computed tomography (CT) imaging phenotype, which has clinical relevance, according to a study ...

Oncology & Cancer

Small molecule could have big impact on cancer

Dr. Jung-Mo Ahn, associate professor of chemistry at The University of Texas at Dallas, has designed and synthesized a novel small molecule that might become a large weapon in the fight against prostate cancer.

Neuroscience

Testosterone beyond sex

When we think about sex hormones, notably estrogens and androgens, we usually associate them with sex, gender and body development. Like all hormones, they are chemical messengers, substances produced in one part of the body ...

page 19 from 32